Organon Patent-Cliff Exposure & CMS Drug Spending Portfolio

Organon (Jersey City, NJ): 30 reconciled FDA prescription therapies (26.8% 2025 to 2030 cliff risk), $696.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterJersey City, NJ
Reconciled FDA Portfolio Therapies30
2025 to 2030 Patent-Cliff Revenue Exposure26.8%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$696.7M
2024 Medicare Part D Spend$234.9M
2024 Medicaid Spend$461.8M
California HCAI SB 17 Filings2 WAC filings (max 67.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Organon across sibling Meru public-data platforms.